Socio-Demographic and Regional Determinants of Late-Stage Prostate Cancer Diagnosis in Brazil’s Public Health System
JCO Global Oncology · 01.11.2026 · 12 (Supplement_1) · 158-159
DOI: 10.1200/go-26-11900 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, erschienen am 01.11.2026. Verfasst von Fernando Augusto Siuta dos Santos und 10 weiteren Autor:innen.
Abstract (Originalsprache)
PURPOSE Prostate cancer remains one of the leading causes of cancer-related mortality among Brazilian men, with delayed diagnosis substantially worsening clinical outcomes. This study aimed to evaluate socio-demographic, regional, and sociocultural disparities associated with advanced-stage prostate cancer diagnosis (stages III and IV) within Brazil’s Unified Health System (SUS). METHODS An ecological and descriptive analysis was conducted using data from the Brazilian Hospital Cancer Registry (RHC/INCA), Ministry of Health epidemiological reports, and national cancer surveillance databases. Clinical stage at first oncologic consultation was assessed across socio-demographic variables, including race, educational attainment, and geographic region. Advanced-stage disease was defined as stage III or IV at diagnosis. RESULTS National RHC data (2012-2021) indicate that over one-third of prostate cancer patients within SUS presented with stage III or IV disease at initial oncologic evaluation, reflecting substantial delays in early detection. Advanced-stage diagnosis disproportionately affected Black and Brown men, individuals with lower educational attainment, and populations in the North and Northeast regions, where access to specialized urologic care and timely diagnostic pathways remains more limited. Lower health literacy, socioeconomic vulnerability, and reduced utilization of preventive healthcare services were strongly associated with delayed presentation. Additionally, sociocultural masculine norms, stigma surrounding preventive examinations, and reluctance to seek early medical care contributed to missed opportunities for timely diagnosis. These intersecting structural and cultural barriers were associated with more aggressive disease presentation, increased morbidity, and poorer oncologic outcomes among vulnerable populations. CONCLUSION Late-stage prostate cancer diagnosis in Brazil reflects a critical convergence of healthcare inequity, socio-demographic vulnerability, and culturally mediated barriers to prevention. Effective public health strategies must expand equitable primary care access, strengthen diagnostic infrastructure in underserved regions, and implement culturally competent educational interventions to improve preventive health engagement among men. Addressing these disparities is essential to reducing avoidable oncologic inequities and improving prostate cancer outcomes in middle-income settings.
Zitieren
APA
Santos, F. A. S. D., Marin, P. D., Scain, G., Fink, I. A., Parise, I. C., Cé, J. L. C., Brum, S. K., Weber, M. W., Sá, M. D., Girardi, R. S., & Melo, S. D. (2026). Socio-Demographic and Regional Determinants of Late-Stage Prostate Cancer Diagnosis in Brazil’s Public Health System. JCO Global Oncology, 12(Supplement_1), 158-159. https://doi.org/10.1200/go-26-11900
Vancouver
Santos FASD, Marin PD, Scain G, Fink IA, Parise IC, Cé JLC, et al. Socio-Demographic and Regional Determinants of Late-Stage Prostate Cancer Diagnosis in Brazil’s Public Health System. JCO Global Oncology. 2026;12(Supplement_1):158-159. doi:10.1200/go-26-11900
BibTeX
@article{Santos2026,
author = {Santos, Fernando Augusto Siuta dos and Marin, Pedro Dytz and Scain, Giulia and Fink, Isabela Alicia and Parise, Isadora Cristyne and Cé, Julia Loureiro Chaves and Brum, Stéphanie Klein and Weber, Mariana Weremeier and Sá, Martina de and Girardi, Rafaela Sumienski and Melo, Solana de},
title = {Socio-Demographic and Regional Determinants of Late-Stage Prostate Cancer Diagnosis in Brazil’s Public Health System},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {Supplement_1},
pages = {158--159},
doi = {10.1200/go-26-11900}
}
EUVIMED